| HOME >> BIOLOGY >> TECHNOLOGY |
Takeda Will Continue to Dominate the Type 2 Diabetes Market, According to a
New Report from Decision Resources
WALTHAM, Mass., Oct. 17 /PRNewswire/ -- Decision Resources and Millennium Research Group have released a new report finding that Merck will obtain blockbuster antidiabetic drug sales in the type 2 diabetes market by 2011, thanks to uptake of their DPP-IV inhibitor, Januvia. Januvia will see rapid uptake as a second-and third-line agent in type 2 diabetes treatment and its success will propel Merck into the diabetes market, giving the company 15 percent of the market in 2011. Januvia will become the second-leading blockbuster in the market, behind only Takeda's Actos. Surveyed primary care physicians ranked Merck as best for product innovation.
"The choice of Merck as 'best' for product innovation in type 2 diabetes indicates physicians' enthusiasm for Januvia," said Elena Rossi, analyst at Millennium Research Group. "This enthusiasm is echoed by the 71 percent of surveyed physicians who believe that Merck will be one of the most influential companies in type 2 diabetes over the next five years."
The report also finds that Takeda led the type 2 diabetes drug market in 2006 with a market share of almost 30 percent from sales of the PPAR-gamma agonist Actos; however, this share will fall to about 21 percent in 2011 due to strong competition from the novel DPP-IV inhibitors (like Januvia) and GLP- 1 analogues (such as Eli Lilly/Amylin's Byetta). Nonetheless, the Actos franchise will continue to gain uptake in the market due in part to the launch of a novel fixed-dose combination of Actos with extended-release metformin. Furthermore, Takeda is developing a novel DPP-IV inhibitor, algoliptin, that is expected to launch in the United States and Europe in 2009 and provide strong competition for Januvia.
About Brands & Strategies
Brands & Strategies is the first and only report series to bring
together all of
'/>"/>
| SOURCE Decision Resources, Inc. Copyright©2007 PR Newswire. All rights reserved |